KOL Views: How strong is Novartis' case for brolucizumab in AMD?

Novartis said last week that brolucizumab (also known as RTH258) proved non-inferior to Eylea (aflibercept) in a pair of Phase III trials to treat wet age-related macular degeneration (AMD), with the added advantages of less frequent dosing – every 12 weeks versus 8 weeks, respectively – and some suggestions of superior efficacy on certain auxiliary measures. (See ViewPoints: Novartis builds an argument in favour of brolucizumab.)

To provide FirstWord readers with rapid feedback on how ophthalmologists are likely to integrate brolucizumab into the treatment algorithm, we are hosting an expert call with a key opinion leader (KOL) on November 17.

Key topics that will be discussed during the call include, among other things… feedback on brolucizumab's safety and efficacy; how does its profile compare to that of Eylea; how compelling is Novartis' contention that brolucizumab dosed every 12 weeks is as good – if not better than – Eylea given every eight weeks; does real-world use of Eylea strengthen or weaken Novartis' argument; how important will it be for Novartis to find a way to pre-identify patients likely to respond to brolucizumab; assuming no surprises, how and when do you expect to use brolucizumab; how important will pricing be for driving prescribing patterns?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to brolucizumab's commercial prospects.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.